Stem Cell Therapeutic and Research Reauthorization Act of 2025

Replaced the fixed requirement of 'at least 150,000 new units of high-quality cord blood' with 'a sufficient supply, as determined by the Secretary, of high-quality cord blood units,' giving the Secretary broad discretion over inventory size.

Added a new inventory management subsection giving the Secretary authority to manage the size and composition of the National Cord Blood Inventory, make determinations about continued storage based on scientific evidence, and prioritize collection, retention, or disposition of units.

Added a new definition of 'high quality cord blood unit' as one that meets current industry standards and any FDA requirements.

Struck the phrase 'in perpetuity or' from Section 2(c)(2), removing language that implied indefinite duration for certain obligations.

Added a new provision requiring the Secretary to consider current scientific and clinical information when entering or extending cord blood bank contracts, replacing prior contract duration language.

Added authority for the Secretary to transfer cord blood units to another qualified bank if a bank becomes non-operational or fails to meet quality requirements, ensuring continued availability.

Changed the authorization of appropriations from fiscal years 2022 through 2026 to fiscal years 2027 through 2031, shifting the funding window forward by five years.